



Now ideas for wellness

From June 2021, the Meiji Group adopted a renewed Group Slogan, “Now ideas for wellness”. The Meiji Group has been trying to spread the world of Tastiness, Enjoyment, Health and Reassurance for more than 100 years. We will integrate the food and pharmaceutical expertise we have accumulated both inside and outside our Group to create cutting-edge value. We will focus on health and play an integral role in the health field.



Consolidated Performance and Share Price in Recent Years

*After applying revenue recognition standards



Major Shareholders


(as of March 31, 2021)

	Number of shares held (Thousands)	Percentage of total shares issued (%)
The Master Trust Bank of Japan, Ltd. (Trust Account)	16,337	10.69
Custody Bank of Japan, Ltd. (Trust Account)	7,756	5.08
Nippon Life Insurance Company	3,348	2.19
Mizuho Bank, Ltd.	3,117	2.04
The Norinchukin Bank	2,892	1.89
Meiji Holdings Trading-Partner Shareholding Association	2,649	1.73
Meiji Holdings Employee Shareholding Association	2,620	1.71
Resona Bank, Limited	2,347	1.53
STATE STREET BANK WEST CLIENT - TREATY 505234	2,242	1.46
Custody Bank of Japan, Ltd. (Trust Account 5)	2,037	1.33

* In addition to the above-mentioned shares, the Company owns 7,584 thousands shares of treasury stock (a 4.97% shareholding).

Shareholding by Type of Shareholder

(as of March 31, 2021)



Financial Institutions	40.25%
Individuals and Others	26.24%
Foreign Companies, etc.	21.24%
Other Companies	9.77%
Financial Instruments Dealers	2.50%

Government and Public Bodies —
* "Individuals and Others" includes treasury stock.

External Recognition

MEMBER OF
Dow Jones Sustainability Indices

In collaboration with **SAM**

ACCESS TO **NUTRITION INDEX™**

Corporate Governance (as of June 29, 2021)

Company with audit & supervisory board members

Directors:	8
Independent outside directors	3 (37.5%)
Women	2 (25.0%)

Inquiries

PR & IR Group, PR & IR Department, Meiji Holdings Co., Ltd.

✉ E-mail ir-info@meiji.com

🌐 Web www.meiji.com/investor/


2023 Medium-term Business Plan (FYE March 2022-2024)

Concept 「Promote the Meiji ROESG®* Management effectively」
 Realize both profit growth and sustainability activities

- Key Issues**
- Business strategy
 - Food segment
 - Recover from the slump in our core business
 - Accelerate growth in our business overseas
 - Pharmaceutical segment
 - Strengthen vaccine business
 - Expand CMO/CDMO business
 - Overall group
 - Venture into new fields
 - Improve business management using ROIC effectively
 - Investing to grow business while constructing strong financial base
 - Promote the Meiji Group Sustainability 2026 Vision

Financial strategy

- Apply ROIC towards strengthening our business management structure and improving capital productivity.
- Reduce cross-shareholding by 30% (based on book value).




Find out more about The Meiji ROESG®
<https://www.meiji.com/global/investors/business-plans/mid-term-plan/>


The Meiji ROESG® = ROE × Achieve ESG goals + Indicators unique to Meiji

Food Segment

Net Sales / Operating Profit *



Breakdown of Sales



Overseas business

[Main products]

- CHINA
 - Yogurt
 - Chilled milk
 - Sports protein
 - Chocolate
 - Ice cream



- ASIA
 - Chocolate snacks



- US
 - Chocolate snacks
 - Crackers



Market Share of Main Products

Yogurt

Share **41.2%** [No.1]
 Market size JPY486.5 bn
 Source: INTAGE Inc., SRI



Powdered & Granulated protein

Share **39.6%** [No.1]
 Market size: JPY47.9 bn
 Based on Meiji data as of FYE March 2021




Chocolate

Share **24.7%** [No.1]
 Market size: JPY414.2 bn
 Source: INTAGE Inc., SRI




Pharmaceutical Segment

Net Sales · Operating Profit *



Breakdown of Sales



Overseas business

[Main products]

- MEIACT (an antibacterial drug)
- ADANT (a treatment for reducing arthritic pain in the joints)



[Production sites]
 In China, Thailand, India, Indonesia and Spain

Market Share of Main Products

Copyright © 2021 IQVIA. *Definition of Meiji
 Calculated based on JPM 2021 Mar MAT
 Reprinted with permission

Systemic antibacterial drugs

Share **19.0%** [No.1]
 Market size: JPY149.2 bn



Influenza Vaccine

Share **28.8%** [No.1]
 Market size: JPY97.0 bn



* Before applying revenue recognition standards